

CORTEX PHARMACEUTICALS INC/DE/  
Form 8-K  
October 04, 2012

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**Form 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): 09/28/2012**

**CORTEX PHARMACEUTICALS INC/DE/**  
(Exact name of registrant as specified in its charter)

**Commission File Number: -**

**DE**  
(State or other jurisdiction of  
incorporation)

**330303583**  
(IRS Employer  
Identification No.)

**7700 Irvine Center Drive, Suite 750, Irvine, CA 92618**  
(Address of principal executive offices, including zip code)

**949 727 3157**  
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

Effective September 28, 2012 and October 1, 2012, respectively, Peter W. Letendre, Pharm.D. and David W. Carley, Ph.D. resigned as members of the Board of Directors of Cortex Pharmaceuticals, Inc.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORTEX PHARMACEUTICALS INC/DE/

Date: October 04, 2012

By: /s/ Maria S. Messinger

---

Maria S. Messinger  
Vice President and Chief Financial Officer